Literature DB >> 33715059

Toward a new landscape for the mechanism of immunosuppression in hepatocellular carcinoma.

Chien-Wei Su1,2,3,4, Han-Chieh Lin5,6.   

Abstract

Entities:  

Keywords:  Biomarkers; Hepatocellular carcinoma; Systemic therapy

Year:  2021        PMID： 33715059     DOI： 10.1007/s12072-021-10161-2

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   6.047


× No keyword cloud information.
  2 in total

1.  Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma.

Authors:  Fei Fan; Keji Chen; Xiaoliang Lu; Aijun Li; Caifeng Liu; Bin Wu
Journal:  Hepatol Int       Date:  2020-11-21       Impact factor: 6.047

2.  Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.

Authors:  Richard S Finn; Baek-Yeol Ryoo; Philippe Merle; Masatoshi Kudo; Mohamed Bouattour; Ho Yeong Lim; Valeriy Breder; Julien Edeline; Yee Chao; Sadahisa Ogasawara; Thomas Yau; Marcelo Garrido; Stephen L Chan; Jennifer Knox; Bruno Daniele; Scot W Ebbinghaus; Erluo Chen; Abby B Siegel; Andrew X Zhu; Ann-Lii Cheng
Journal:  J Clin Oncol       Date:  2019-12-02       Impact factor: 44.544
  2 in total
  1 in total

Review 1.  Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches.

Authors:  Suresh Gopi Kalathil; Yasmin Thanavala
Journal:  Cells       Date:  2021-05-28       Impact factor: 6.600
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.